Interleukin 1 Beta Inhibitors Pipeline Insight

DelveInsight’s, “Interleukin 1 Beta Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interleukin 1 Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Interleukin 1 Beta Inhibitors Understanding

Interleukin 1 Beta Inhibitors: Overview

Interleukin 1 Beta Inhibitors is a potent pro-inflammatory cytokine produced by cells of the innate immune system. Interleukin 1 beta (IL-1β) is produced as an inactive 31 kDa precursor, termed pro-IL-1β, in response to molecular motifs carried by pathogens called ‘pathogen associated molecular patterns’ (PAMPs). It is a major cytokine involved in monocyte activation and activation of proinflammatory signaling pathways in peripheral tissues and brain. IL-1β expression and its secretion are tightly regulated. IL-1β is a master regulator of inflammation via controlling a variety of innate immune processes. IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF). The blocking of IL-1 could be effective strategies for the management of classic autoimmune diseases and autoinflammatory diseases.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 1 Beta Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 1 Beta Inhibitors.

Interleukin 1 Beta Inhibitors Emerging Drugs Chapters

This segment of the Interleukin 1 Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Interleukin 1 Beta Inhibitors Emerging Drugs


Gevokizumab: Novartis

Gevokizumab (VPM087) is a novel, human-engineered monoclonal anti - IL-1β antibody. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine. The drug is in Phase I clinical studies for the treatment of patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.


Goflikicept: TRPHARM

Goflikicept (RPH-104) is a heterodimeric fusion protein containing IL-1R1 and IL-1RAcP linked to immunoglobulin heavy chains and is highly selectively binds IL-1β. TRPHARM is evaluating Goflikicept in Phase II/III clinical studies for the treatment of Pericarditis and in Phase II clinical studies for Gout Attack and myocardial infarction.

Further product details are provided in the report……..

Interleukin 1 Beta Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin 1 Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players working on Interleukin 1 Beta Inhibitors

There are approx. 11+ key companies which are developing the Interleukin 1 Beta Inhibitors. The companies which have their Interleukin 1 Beta Inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, TRPHARM.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Interleukin 1 Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin 1 Beta Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 1 Beta Inhibitors therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 1 Beta Inhibitors drugs.

Interleukin 1 Beta Inhibitors Report Insights

  • Interleukin 1 Beta Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Interleukin 1 Beta Inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Interleukin 1 Beta Inhibitors drugs?
  • How many Interleukin 1 Beta Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Interleukin 1 Beta Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin 1 Beta Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interleukin 1 Beta Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Interleukin 1 Beta Inhibitors: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration

Interleukin 1 Beta Inhibitors – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Interleukin 1 Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Interleukin 1 Beta Inhibitors Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II/III)

  • Comparative Analysis

Goflikicept: TRPHARM

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Gevokizumab: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

FL-101: Flame Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Interleukin 1 Beta Inhibitors Key Companies

Interleukin 1 Beta Inhibitors Key Products

Interleukin 1 Beta Inhibitors- Unmet Needs

Interleukin 1 Beta Inhibitors- Market Drivers and Barriers

Interleukin 1 Beta Inhibitors- Future Perspectives and Conclusion

Interleukin 1 Beta Inhibitors Analyst Views

Interleukin 1 Beta Inhibitors Key Companies

Appendix

List of Table

Table 1: Total Products for Interleukin 1 Beta Inhibitors  

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Interleukin 1 Beta Inhibitors

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Novartis

• Regeneron Pharmaceuticals

• TRPHARM

• Hutchison MediPharma

• Tetra Bio Pharma

• Jiangsu T-mab BioPharma

• Flame Biosciences

Forward to Friend

Need A Quote